160 related articles for article (PubMed ID: 24619827)
1. Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation.
Sakurai M; Mori T; Kato J; Koda Y; Kikuchi T; Kohashi S; Saburi M; Toyama T; Aisa Y; Nakazato T; Beppu N; Tsuda S; Shigematsu N; Okamoto S
Int J Hematol; 2014 Apr; 99(4):457-62. PubMed ID: 24619827
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
4. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.
Bechtel T; McBride A; Crawford B; Bullington S; Hofmeister CC; Benson DM; Jaglowski S; Penza S; Andritsos LA; Devine SM
Support Care Cancer; 2014 Nov; 22(11):2911-6. PubMed ID: 24838259
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT).
Bubalo J; Mulverhill K; Meyers G; Hayes-Lattin B; Maziarz R
Bone Marrow Transplant; 2018 Aug; 53(8):1010-1018. PubMed ID: 29459665
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation.
Uchida M; Kato K; Ikesue H; Ichinose K; Hiraiwa H; Sakurai A; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Teshima T; Shiratsuchi M; Suetsugu K; Nagata K; Egashira N; Akashi K; Oishi R
Pharmacotherapy; 2013 Sep; 33(9):893-901. PubMed ID: 23712662
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of palonosetron, fosaprepitant, and olanzapine as antiemetic prophylaxis for fludarabine and melphalan-based conditioning regimens prior to allogeneic hematopoietic stem cell transplants.
Karpen R; Sen J; Wall S; Musson S; Tossey J
Leuk Res; 2024 Jan; 136():107431. PubMed ID: 38043326
[TBL] [Abstract][Full Text] [Related]
9. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
10. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.
Stiff PJ; Fox-Geiman MP; Kiley K; Rychlik K; Parthasarathy M; Fletcher-Gonzalez D; Porter N; Go A; Smith SE; Rodriguez TE
Biol Blood Marrow Transplant; 2013 Jan; 19(1):49-55.e1. PubMed ID: 22863840
[TBL] [Abstract][Full Text] [Related]
11. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Kim HJ; Shin SW; Song EK; Lee NR; Kim JS; Ahn JS; Yun HJ; Cho YH; Park KU; Kim SY; Jang JS; Kim SW; Lee HW; Lee SR; Kim YS; Lee SN; Ko YH; Kim HJ; Kang JH
Oncologist; 2015 Dec; 20(12):1440-7. PubMed ID: 26512046
[TBL] [Abstract][Full Text] [Related]
12. Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study.
Isoda A; Saito R; Komatsu F; Negishi Y; Oosawa N; Ishikawa T; Miyazawa Y; Matsumoto M; Sawamura M; Manaka A
Int J Hematol; 2017 Apr; 105(4):478-484. PubMed ID: 27873176
[TBL] [Abstract][Full Text] [Related]
13. Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.
Ye P; Pei R; Wang T; Cao J; Zhang P; Chen D; Liu X; Du X; Li S; Tang S; Hu Y; Jiang L; Lu Y
Ann Hematol; 2022 Aug; 101(8):1835-1841. PubMed ID: 35668198
[TBL] [Abstract][Full Text] [Related]
14. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Clark SM; Clemmons AB; Schaack L; Garren J; DeRemer DL; Kota VK
J Oncol Pharm Pract; 2016 Jun; 22(3):416-22. PubMed ID: 25956421
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Inoue T; Kimura M; Uchida J; Nishino K; Kumagai T; Taniguchi J; Imamura F
Int J Clin Oncol; 2017 Jun; 22(3):600-604. PubMed ID: 28144884
[TBL] [Abstract][Full Text] [Related]
17. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
[TBL] [Abstract][Full Text] [Related]
18. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Jordan K; Jahn F; Jahn P; Behlendorf T; Stein A; Ruessel J; Kegel T; Schmoll HJ
Bone Marrow Transplant; 2011 Jun; 46(6):784-9. PubMed ID: 20838387
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA
Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796
[TBL] [Abstract][Full Text] [Related]
20. Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions.
Tendas A; Marchesi F; Mengarelli A; Annibali O; Tomarchio V; Saltarelli D; Chierichini A; Di Venanzio M; Sollazzo F; Piedimonte M; Cupelli L; Bruno A; De Angelis G; Delbono L; Niscola P; Perrotti AP; de Fabritiis P; Arcese W;
Support Care Cancer; 2019 Mar; 27(3):793-803. PubMed ID: 30564934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
